Studies: One Dose of "Psilocybin" from Magic Mushrooms Relieves Depression in 80% of Cancer Patients
New studies from NYU and John Hopkins University show the effectiveness of psilocybin in treating depression and anxiety of cancer patients.
The largest studies to date, by arguably the most respected institutions up to this point, show that psilocybin, a compound within "magic mushrooms", can be effective in treating depression and anxiety in cancer patients.
The studies were carried out on 29 patients by researchers at New York University (NYU) and on 51 patients at Johns Hopkins University.
Notably, up to 40% of all cancer patients are afflicted by psychological issues related to their illness.
Around 80% of the cancer patients in the studies got noticeably better after just one dose. And they sustained the psychological gains they made for up to seven months, with few minor side effects. Patients reported improvements in their quality of life, having more energy, going out more and having better relationships with family members.
Interestingly, those who had a stronger trip reported the strongest gains in alleviating their depression and anxiety.
A number of authorities in psychiatry and addiction medicine expressed their support for the work. These include Dr. Jeffrey Lieberman, a former president of the American Psychiatric Association and Dr. Daniel Shalev from the New York State Psychiatric Institute, who wrote that the studies are ”a model for revisiting criminalized compounds of interest in a safe, ethical way.”
The studies were also reviewed by regulators and were described by the New York Times as "most meticulous" to date.
The lead author of the Johns Hopkins study, psychiatrist Dr. Roland Griffiths, was optimistic on the possibilities of the new treatment, likening it to a groundbreaking surgery rather than the painstaking work to make feel people better used by traditional psychiatric approaches.
“I really don’t think we have any models in psychiatry that look like” the effects demonstrated in the two trials, said Griffiths. “Something occurs and it’s repaired and it’s better going forward … very plausibly for more than six months,” he added. “In that sense it’s a new model.”
One of the participants in the study, Sherry Marcy, described the changes in how she felt this way:
"The cloud of doom seemed to just lift… I got back in touch with my family and kids, and my wonder at life," said Marcy, whose been battling cancer from 2010. "Before, I was sitting alone at home, and I couldn't move … This study made a huge difference, and it's persisted."
Psilocybin-containing "magic mushrooms". Credit: Getty Images.
The particulars of both studies involved randomly offering patients either psilocybin or a placebo at the first session, and then giving them the opposite treatment seven weeks later. This way all participants eventually took psilocybin. In both studies, the success rate of psilocybin versus the placebo was very clear, with 83% getting better on psilocybin and only 14% on the placebo in the NYU study.
Psilocybin, of course, have been banned in the U.S. for over 40 years. While they were allowed to use it for their studies, the scientists warn against self-medicating depression by taking "magic mushrooms". They caution that professionals are needed to control the dosage and provide a supportive environment in which to experience the drug's effects. The psilocybin therapy may also not be appropriate for people with schizophrenia or young adults.
To move forward in this field, Dr. Shalev and Dr. Lieberman see a need to loosen research restrictions, because "there is much potential for new scientific insights and clinical applications.” Ideally, the next step would be a trial with a larger sample, perhaps across several centers with hundreds of subjects.
Not everyone is on board. Dr. William Breitbart, chairman of the psychiatry department at the Memorial Sloan-Kettering Cancer Center expressed his reservations about the use of cancer patients for the study.
“Medical marijuana got its foot in the door by making the appeal that ‘cancer patients are suffering, they’re near death, so for compassionate purposes, let’s make it available,’ ” he said. “And then you’re able to extend this drug to other purposes.”
The positive effect of psilocybin on depression was also demonstrated by studies earlier this year.
Cover photo credit: Langone Medical Center/New York University.
- The meaning of the word 'confidence' seems obvious. But it's not the same as self-esteem.
- Confidence isn't just a feeling on your inside. It comes from taking action in the world.
- Join Big Think Edge today and learn how to achieve more confidence when and where it really matters.
- Economist Sylvia Ann Hewlett breaks down what qualities will inspire others to believe in you.
- Here's how 300 leaders and 4,000 mid-level managers described someone with executive presence.
- Get more deep insights like these to power your career forward. Join Big Think Edge.
Upstreamism advocate Rishi Manchanda calls us to understand health not as a "personal responsibility" but a "common good."
- Upstreamism tasks health care professionals to combat unhealthy social and cultural influences that exist outside — or upstream — of medical facilities.
- Patients from low-income neighborhoods are most at risk of negative health impacts.
- Thankfully, health care professionals are not alone. Upstreamism is increasingly part of our cultural consciousness.
It marks a major shift in the government's battle against the opioid crisis.
- The nation's sixth-largest drug distributor is facing criminal charges related to failing to report suspicious drug orders, among other things.
- It marks the first time a drug company has faced criminal charges for distributing opioids.
- Since 1997, nearly 222,000 Americans have died from prescription opioids, partly thanks to unethical doctors who abuse the system.
SMARTER FASTER trademarks owned by The Big Think, Inc. All rights reserved.